Table 3 |
||||||||
|
Treatment, Follow-Up, and Prognosis of Recently Reported Xp11.2 Translocation Renal Cell Carcinomas in Patients Aged 16 or Older |
||||||||
|
Treatment |
Pattern of Progression |
|||||||
|
|
||||||||
|
Source, Year |
Pts, No. |
Age, y/Sex |
Primary Treatment |
Additional Treatment |
Local Recurrence |
Metastases |
Follow-Up Time, y |
Outcome |
|
|
||||||||
|
Dal Cin et al, 1998 [10] |
1 |
53/F |
RN |
Resection of metastases |
None |
Lung, bone, liver, adrenal, retroperitoneal LNs |
31 |
NS |
|
|
||||||||
|
Salles and Soto, 2005 [11] |
1 |
58/F |
RN |
None |
None |
Renal hilar LNs |
0.5 |
FOD |
|
|
||||||||
|
Mansouri et al, 2006 [12] |
1 |
16/F |
RN |
Resection of metastases, ChemoRx, IFN-α, IL-2 |
Yes |
Lung, bone, adrenal, lumbar-aortic LNs |
NS |
NS |
|
|
||||||||
|
Schinstine et al, 2006 [13] |
1 |
57/F |
RN |
Resection of metastases |
None |
Lung |
1 |
NS |
|
|
||||||||
|
Meyer et al, 2007 [14] |
5 |
32.6 (mean)/5M |
4 RN; 1 renal Bx |
Resection of metastases, ChemoRx, XRT, IL-2, investigational agents |
Yes |
Lung, bone, liver, brain, mediastinal LNs |
1.5 (mean) |
2 DOD |
|
|
||||||||
|
Rais-Bahrami et al, 2007 [15] |
1 |
23/M |
RN |
Resection of metastases, ChemoRx, investigational agents |
None |
Lung, liver, retroperitoneal, supraclavicular, cervical and mediastinal LNs |
17 |
DOD |
|
|
||||||||
|
Suzigan et al, 2007 [16] |
1 |
17/F |
PN |
None |
None |
None |
0.33 |
FOD |
|
|
||||||||
|
Argani et al, 2007 [17] |
28 |
22–68 (range)/22F, 6M |
NS |
NS |
NS |
5 hematogenous metastases |
NS |
2 DOD |
|
|
||||||||
|
Armah and Parwani, 2008 [18] |
1 |
33/M |
RN |
Resection of metastases, ChemoRx, XRT, IFN-α, IL-2 |
None |
Lung, liver, bone, brain, mediastinal LNs |
0.58 |
DOD |
|
|
||||||||
|
Camparo et al, 2008 [19] |
31 |
24.6 (mean)/18F, 13M |
30 RN; 1 renal Bx |
Resection of metastases, ChemoRx, XRT, IFN-α, IL-2, investigational agents |
NS |
Lung, liver, bone, LNs |
0.5–7.67 (range) |
5 DOD |
|
|
||||||||
|
Wu et al, 2008 [9] |
3 |
17–20 (range)/1F, 2M |
3RN |
Resection of metastases, investigational agents |
Yes |
Retroperitoneal LNs |
1.7–3.4 (range) |
1 DOD |
|
|
||||||||
|
Gellar et al, 2008 [20] |
4 |
16–17 (range)/3F, 1M |
4RN |
ChemoRx, IFN-α, IL-2, investigational agents |
None |
Lung, liver |
1.17–15.42 (range) |
1 DOD |
|
|
||||||||
|
Hintzy et al, 2008 [21] |
6 |
28–42 (range)/4F, 2M |
NS |
NS |
NS |
3 hematogenous metastases |
2.67 (mean) |
1 DOD |
|
|
||||||||
|
Komai et al, 2009 [22] |
6 |
24–59 (range)/2F, 4M |
6RN |
Resection of metastases, IFN-α, IL-2 |
None |
Lung, liver, LNs |
0.75–11 (range) |
2 DOD |
|
|
||||||||
|
Bovio et al, 2009 [23] |
1 |
20/F |
RN |
NS |
None |
Placenta, bone, retroperitoneal LNs |
2 |
NS |
|
|
||||||||
|
Koie et al, 2009 [24] |
1 |
28/M |
RN |
Resection of metastases, IFN-α, IL-2 |
Yes |
Lung, liver, adrenal, spleen, pancreas, psoas muscle, mesentery, descending colon, retroperitoneal LNs |
2 |
DOD |
|
|
||||||||
|
Bx, biopsy; ChemoRx, chemotherapy; DOD, died of disease; F, female; FOD, free of disease; IFN-α, interferon-α; IL-2, interleukin-2; LNs, lymph nodes; M, male; No., number; NS, not specified; PN, partial nephrectomy; Pts, patients; RN, radical nephrectomy; XRT, radiotherapy; y, years |
||||||||
|
Armah et al. Diagnostic Pathology 2009 4:15 doi:10.1186/1746-1596-4-15 |
||||||||
